AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

📰

Systemic lupus erythematosus: the latest breakthroughs

Everything that changed in the last year, from three public sources: phase 3 trials that posted their results, papers in the leading medical and cancer journals, and US drug labels that were updated. Refreshed every week.

🤖

What changed

Written by AI from the evidence below, every point cited

AI reads the results, papers and label updates below and explains what changed and why it matters, citing each source. It is shared with everyone.

🏁

Phase 3 results posted

The large trials that decide new standard treatments · ClinicalTrials.gov
Anifrolumab Asian PhIII Efficacy Study for Systemic Lupus Erythematosus (SLE)NCT04931563 · results posted 2026-05-20 · AstraZeneca · 277 people · tests Anifrolumab, placebo Evaluate Efficacy, Safety and Tolerability, PK and PD of Emapalumab in Children and Adults With MAS in Still's or SLENCT05001737 · results posted 2026-02-19 · Swedish Orphan Biovitrum · 33 people · tests Emapalumab A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With ISN/RPS 2003 Class III or IV Lupus NephritisNCT04221477 · results posted 2025-11-06 · Hoffmann-La Roche · 271 people · tests Obinutuzumab, MMF, Prednisone, Placebo
📚

In the leading journals

NEJM, Lancet, Nature, JCO, Cancer Cell and more · PubMed
Dalmelitinib Plus Aumolertinib in Advanced NSCLC Patients With EGFR-TKI Resistance and MET Amplification: A Randomized Phase 3 Trial.J Clin Oncol 2026 · PMID 42928710 Cardiovascular resilience in centenarians.Nat Rev Cardiol 2026 · PMID 42928381 ctDNA clearance and outcomes for resectable lung cancer from NeoCOAST-2.Nature 2026 · PMID 42927884 Clinical Complete Response with Dostarlimab Monotherapy in dMMR/MSI-H Locally Advanced Rectal Cancer: First Results from the Global AZUR-1 …Ann Oncol 2026 · PMID 42927858 From Diagnosis to Destruction: The Rise of Radioligand Therapeutics as Oncology's New Pillar.Ann Oncol 2026 · PMID 42927857 Pembrolizumab plus lenvatinib with belzutifan or quavonlimab as first-line therapy for advanced renal-cell carcinoma: randomized open-label…Ann Oncol 2026 · PMID 42927856 Final prespecified analysis of the phase 3 LITESPARK-011 study: belzutifan plus lenvatinib versus cabozantinib for advanced renal cell carc…Ann Oncol 2026 · PMID 42927855 Pembrolizumab with or without platinum-based chemotherapy as first-line treatment in advanced NSCLC expressing PD-L1 ≥50%: The PERSEE rando…Ann Oncol 2026 · PMID 42927854 A randomised phase III trial of adjuvant treatment intensification with mFOLFIRINOX versus mFOLFOX6 in high-risk stage III colon cancer: Re…Ann Oncol 2026 · PMID 42927853 Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer …Lancet Oncol 2026 · PMID 42927765 Neoadjuvant nivolumab with or without visugromab in muscle-invasive bladder cancer: the phase 2a GDFATHER-NEO trial.Nat Med 2026 · PMID 42926233 Relatlimab plus nivolumab versus nivolumab for advanced melanoma: 5-year survival and biomarker analyses of the phase 3 RELATIVITY-047 tria…Nat Med 2026 · PMID 42926136

Want these every week? Follow systemic lupus erythematosus and get a note on your phone with the new trials and papers.

🔔 Follow systemic lupus erythematosus
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy